share_log

Citigroup Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $14

Citigroup Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $14

花旗集團維持對ORIC製藥的買入,將目標股價下調至14美元
Benzinga ·  05/07 13:37

Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and lowers the price target from $15 to $14.

花旗集團分析師伊加爾·諾霍莫維茨維持ORIC Pharmicals(納斯達克股票代碼:ORIC)的買入並將目標股價從15美元下調至14美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論